Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_assertion type Assertion NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_head.
- NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_assertion description "[Among the patients with myelofibrosis, those with ASXL1 lesions were not distinguished from their wild-type counterparts with regard to JAK2 V617F status, exposure to chemotherapy or evolution to leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_provenance.
- NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_assertion evidence source_evidence_literature NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_provenance.
- NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_assertion SIO_000772 21712540 NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_provenance.
- NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_assertion wasDerivedFrom befree-20150227 NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_provenance.
- NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_assertion wasGeneratedBy ECO_0000203 NP519234.RADXHlE3z6MUA6YRfuSECiWxxlJROM9xPzRCC3FkeC3g0130_provenance.